How Can The Benefits Of Breast Cancer Screening Be Extended?

August 07, 1998

(Cost effectiveness of shortening screening interval or extending age range of NHS breast screening programme: computer simulation study)

(Routine invitation of women aged 65-69 for breast cancer screening: results of first year of pilot study)

(Extending the benefits of breast cancer screening. Still hard to know how large the benefits will really be)

The NHS breast screening programme, introduced in 1988, currently provides mammography for women aged 50-64 years every three years. But what if they were screened more often and what if the programme was extended to women of 69 years of age? These questions are tackled in a study reported in this week's BMJ by Rob Boer from Erasmus University in Rotterdam and colleagues from the UK.

The current breast screening programme reduces deaths from breast cancer by 12.8 per cent. The authors estimate that by extending the programme to women aged 69 it would reduce deaths by 16.4 per cent (at a marginal cost per life saved of £2990), while reducing the interval to two years would reduce mortality by 15.3 per cent at a marginal cost per life saved of £3545.

Boer et al conclude that either of these two options for extending the programme would reduce deaths substantially if only the budget for the NHS screening programme could accommodate it.

But if the programme was extended to older women (who are more likely than younger women to develop breast cancer), would they turn up for further screens? Yes, is the overwhelming answer, according to Dr Linda Garvican from the South East Institute of Public Health in Kent along with colleagues from Sussex and Surrey. In a short report published in this week's BMJ, the authors found that over 70 per cent those women who had previously attended for breast screening would continue to do so after the age of 64 years (even if they hadn't been invited for six years).

In a linked editorial Dr Ursula Werneke and Professor Klim McPherson from the London School of Hygiene and Tropical Medicine conclude that the two studies reported are important, but their findings may only have a limited validity. They argue that before any of the suggested changes to the current system are implemented, further discussion on the potential opportunity costs should be undertaken.

Contact:

Rob Boer, Informatician, Department of Public Health, Institut Maatschappelijke Gezondheidszorg, Erasmus University, Rotterdam, Netherlands

Dr Linda Garvican, Principal Public Health Specialist, South East Institute of Public Health, Tunbridge Wells, Kent

Professor Klim McPherson, Professor of Public Health Epidemiology, Cancer and Public Health Unit, London School of Hygiene and Tropical Medicine, London
-end-


BMJ

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.